Evaluation of OCT2‐mediated drug-drug interactions between ulotaront and metformin in subjects with schizophrenia
Abstract Ulotaront (SEP‐363856) is a TAAR1 agonist, with 5‐HT1A agonist activity, currently in clinical development for the treatment of schizophrenia. In vitro studies indicate ulotaront is an OCT2‐specific inhibitor with IC50 of 1.27 μM. The primary objective of this study is to determine if a sin...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Book |
| Published: |
Wiley,
2024-04-01T00:00:00Z.
|
| Subjects: | |
| Online Access: | Connect to this object online. |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|